Appointments at Euthymics, CytomX, NPS Pharmaceuticals and InQ Biosciences – People on the move
Pedro Granadillo has been appointed to the board of directorsat NPS Pharmaceuticals. Granadillo worked at Eli Lilly for 34 years, retiring from the position of senior vice president (SVP) of global manufacturing and human resources in 2004.
Euthymics Bioscience has added manufacturing expertise by appointing Walter Piskorski as VP, technical operations. Piskorski held similar positions at Orexigen and Sepracor. Earlier in his career Piskorski worked at Baxter and Bristol-Myers Squibb (B-MS).
Mark Rolfe has joined CytomX Therapeutics as chief scientific officer. Rolfe has more than 20 years of experience in oncology drug discovery and development working at companies including Facet Biotech and Millennium Pharmaceuticals.
CytomX has also hired Henry Lowman as VP, research. Lowman joins CytomX from NGM Biopharmaceuticals, where he was director of protein sciences. He also worked at Genentech for 20 years.
InQ Biosciences has appointed Michael Chambers and John Cooper to its board of directors. Chambers is CEO of Swift Biotechnology and helped establish InnoRx Pharmaceuticals. Cooper is the former chairman and CEO of Avocent.
Jasbir Seehra has stepped down as chief scientific officer at Acceleron Pharma. Seehra co-founded Acceleron and has now left to pursue other interests, although he will maintain a consulting relationship.
PolyMedix has named Steffen Helming as VP of business development. Helming previously worked as EVP, business development at Noxxon Pharma. In this capacity Helming worked with a number of big pharma, including Pfizer, Roche and Eli Lilly.
Kristine Peterson has joined the board of directors at Amarin. Peterson worked at B-MS for 20 years, is the current CEO of Valeritas and has also held positions at Johnson & Johnson and Biovail.
